Imagion Biosystems announced that it has received a total of $143,157 for the exercise of options.
Composed of $142,200 for 2,370,000 options exercisable at 6 cents and expiring on 27 November 2020 and $957 for the exercise of 31,900 listed options exercisable at 3 cents and expiring on 28 April 2023.
Read the announcement.
https://youtu.be/hThLkmpJPW0 EGM 13 November 2023 Video transcript: Welcome and thanks for joining us. Both those joining virtually and those in person. As the time is
Highlights: Announced preliminary performance of MagSense® HER2 Imaging Agent in phase 1 study after study closure (post quarter end) Entered a strategic partnership with Prestige
Earlier this month, Imagion announced our upcoming EGM meeting to be held on 13th November, along with several resolutions to be voted on by shareholders. Here, Imagion
We’re on a mission to make cancer more detectable.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance
